The field of multiple myeloma has transformed from having few treatments to an abundance of effective drugs. The primary clinical challenge is no longer finding a therapy that works, but rather determining the optimal sequence and combination of available options, highlighting a unique form of market maturity.

Combining Bellemaf with VRd induction for newly diagnosed, transplant-ineligible myeloma yields 100% response rates. This potent efficacy is driving its adoption in earlier treatment lines, with the clinical focus shifting to proactively managing its known ocular toxicities through dose adjustments and holds.

When a highly effective therapy like EV Pembro was approved for 'cisplatin ineligible' patients, the definition of 'ineligible' became very elastic in practice. This demonstrates that when a new treatment is seen as transformative, clinicians find ways to qualify patients, putting pressure on established guidelines.

With highly effective treatments like CAR-T and bispecifics moving into earlier lines of therapy for multiple myeloma, the clinical focus must evolve. While efficacy benchmarks have been met, the next advancement requires vigilant attention to safety, particularly infection risks and other side effects of new paradigms.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

Traditional age cutoffs for AML therapy are becoming obsolete. A comprehensive fitness assessment, not just chronological age, should guide treatment, as some guidelines now classify patients as young as 55 as "older adults," a surprising shift for many clinicians.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

CARTITUDE-IV trial data challenges the idea of reserving CAR-T therapy for high-risk myeloma. In early relapse, standard-risk patients treated with siltacel had a longer progression-free survival than even high-risk patients on the same therapy. This suggests standard-risk patients may gain the most relative benefit from earlier CAR-T intervention compared to standard of care.

In newly diagnosed, transplant-ineligible myeloma, an iberdomide-based triplet (Iber-Dara-Dex) achieved 64% MRD negativity. This result is described as "astounding" because achieving MRD negativity is not even a realistic goal for comparable IMiD-based triplets like Dara-Len-Dex (the MAYA regimen). This sets a dramatically higher efficacy bar for frontline treatments.